Drug
Arv 393
Arv 393: highest development phase Phase 1, developed by Arvinas. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Arvinas
Trials
| Drug | Phase | Indication |
|---|---|---|
| ARV-393 NCT06393738 | Phase 1 | Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) |
Latest
No recent events.
Follow Arv 393 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.